Caris Life Sciences, Inc. CAI

Caris Life Sciences® (Caris), a leading AI TechBio company, today unveiled the enhanced Caris Assure®, a new evolution of liquid biopsy. By integrating Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and whole-blood analysis (for true CHIP identification) into a single platform, the enhanced Caris Assure assay provides a more complete molecular profile from a single blood draw, delivering deeper insights to help guide precision oncology decisions.

In general, many current shareholders have lived through a deep correction that started after Caris Life Sciences peaked at 42.50 on Aug. 22 last year. Thus, Caris Life Sciences is still extended. Caris Life Sciences uses artificial intelligence and other technology to profile molecules of interest to the life sciences industry.

Key TakeawaysSector Rally: Caris Life Sciences (CAI) stock jumped 9. 61% to close at $31 on Thursday, September 17, riding a Fed-driven market rally and a surge across AI-powered precision oncology peers.

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide®, strengthening relationships across the oncology and pathology communities, and accelerate adoption of the CNSide platform by physicians and health systems. “Samantha brings more than two de

Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the launch of its new national campaign titled, "Math," featuring the iconic, award-winning actor, producer and director, Kevin Costner. The partnership is designed to raise awareness of the critical importance of early cancer detection and introduce a national audience to Caris Detect™, Caris' groundbreaking multi-cancer early detection (MCED) blood test.

Caris Life Sciences (CAI) is drawing fresh attention after announcing that its researchers will present seven lung cancer studies at the 2026 World Conference on Lung Cancer in Seoul this month. For investors, the World Conference presentations and August’s pancreatic cancer AI publication land against a mixed share price backdrop for Caris Life Sciences, with the stock down 28.06% on a 1 year total shareholder return basis but showing strong 90 day share price momentum of 55.33% and a 30 day...

Caris Life Sciences (NasdaqGS: CAI) announced plans to present seven major precision oncology studies at the IASLC 2026 World Conference on Lung Cancer. The company highlighted new data on molecular profiling and AI powered analysis for lung cancer care. Caris also published a validated AI driven method designed to help optimize first line pancreatic cancer treatment choices. For readers following how AI is reshaping cancer research and treatment, it can also be useful to look at other...

Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced that researchers from Caris and the Caris Precision Oncology Alliance® (Caris POA) will present seven studies at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), taking place September 12-15, 2026, in Seoul, South Korea. Caris research includes two mini oral presentations, one Poster Tour presentation and four poster presentations highlighting how comprehe

Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced the publication of a study in npj Precision Oncology describing the development and validation of an AI-driven approach to optimize first-line treatment selection in pancreatic cancer, advancing a more personalized care path for one of the deadliest malignancies.

After soaring by as much as 21.58 percent on Thursday, Caris Life Sciences Inc. (NASDAQ:CAI) heads into the next trading session with investors focused less on a stellar earnings performance and more on whether it can sustain its momentum towards a recovery. To recall, the company reported strong earnings results in the second quarter of […]

Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.

Moby summary of Caris Life Sciences, Inc.'s Q2 2026 earnings call

Caris Life Sciences® (Caris), a leading TechBio company, today announced the publication of a study in Cancer Research Communications demonstrating the ability of a multimodal, multitask deep learning model to estimate late distant recurrence risk in hormone receptor-positive (HR+) early breast cancer.

Caris Life Sciences Inc (CAI) reports 45% revenue growth and raises full-year guidance amid strong molecular profiling performance and strategic product launches.

Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended June 30, 2026.